Roche's Tecentriq Intravenous Cancer Therapy Gets UK Approval
2023年8月29日 - 6:51PM
Dow Jones News
By Giulia Petroni
Roche said the U.K.'s medicines regulator has approved its
Tecentriq intravenous cancer therapy.
The Swiss pharmaceutical company said Tuesday that the therapy
will be available to patients for all indications in which the
formulation has been previously approved, including certain types
of lung, bladder, breast and liver cancer.
Tecentriq SC is Roche's fourth subcutaneous cancer therapy.
The approval granted by the U.K. Medicines and Healthcare
products Regulatory Agency is the first for Tecentriq SC globally.
Evaluations by the U.S. Food and Drug Administration and other
health authorities are currently underway, Roche said.
Write to Giulia Petroni at giulia.petroni@wsj.com
(END) Dow Jones Newswires
August 29, 2023 05:36 ET (09:36 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
Roche (QX) (USOTC:RHHBY)
過去 株価チャート
から 4 2024 まで 5 2024
Roche (QX) (USOTC:RHHBY)
過去 株価チャート
から 5 2023 まで 5 2024
Real-Time news about Roche Holdings Ltd AG (QX) (その他OTC): 0 recent articles
その他のRoche Holdings Ltd AG (QX)ニュース記事